Clinical risk score to predict likelihood of recurrence after ductal carcinoma in situ treated with breast-conserving surgery-Reference-Cited by-同舟云学术

Clinical risk score to predict likelihood of recurrence after ductal carcinoma in situ treated with breast-conserving surgery

Published:2017-10-28 Issue:3 Volume:167 Page:751-759
ISSN:0167-6806
Container-title:Breast Cancer Research and Treatment
language:en
Short-container-title:Breast Cancer Res Treat

Author:

Punglia Rinaa S.^ORCID,Jiang Wei,Lipsitz Stuart R.,Hughes Melissa E.,Schnitt Stuart J.,Hassett Michael J.,Nekhlyudov Larissa,Achacoso Ninah,Edge Stephen,Javid Sara H.,Niland Joyce C.,Theriault Richard L.,Wong Yu-Ning,Habel Laurel A.

Funder

Agency for Healthcare Research and Quality

National Cancer Institute

Publisher

Springer Science and Business Media LLC

Subject

Cancer Research,Oncology

Link

http://link.springer.com/article/10.1007/s10549-017-4553-5/fulltext.html

Reference44 articles.

1. Sumner WE 3rd, Koniaris LG, Snell SE, Spector S, Powell J, Avisar E, Moffat F, Livingstone AS, Franceschi D (2007) Results of 23,810 cases of ductal carcinoma-in-situ. Ann Surg Oncol 14(5):1638–1643

2. Bijker N, Meijnen P, Peterse JL, Bogaerts J, Van Hoorebeeck I, Julien JP, Gennaro M, Rouanet P, Avril A, Fentiman IS et al (2006) Breast-conserving treatment with or without radiotherapy in ductal carcinoma-in-situ: ten-year results of European Organisation for Research and Treatment of Cancer randomized phase III trial 10853–a study by the EORTC Breast Cancer Cooperative Group and EORTC Radiotherapy Group. J Clin Oncol 24(21):3381–3387

3. Fisher B, Land S, Mamounas E, Dignam J, Fisher ER, Wolmark N (2001) Prevention of invasive breast cancer in women with ductal carcinoma in situ: an update of the National Surgical Adjuvant Breast and Bowel Project experience. Semin Oncol 28(4):400–418

4. Emdin SO, Granstrand B, Ringberg A, Sandelin K, Arnesson LG, Nordgren H, Anderson H, Garmo H, Holmberg L, Wallgren A (2006) SweDCIS: radiotherapy after sector resection for ductal carcinoma in situ of the breast. Results of a randomised trial in a population offered mammography screening. Acta Oncol 45(5):536–543

5. Houghton J, George WD, Cuzick J, Duggan C, Fentiman IS, Spittle M (2003) Radiotherapy and tamoxifen in women with completely excised ductal carcinoma in situ of the breast in the UK, Australia, and New Zealand: randomised controlled trial. Lancet 362(9378):95–102

Cited by 15 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Extracellular Microenvironment Alterations in Ductal Carcinoma In Situ and Invasive Breast Cancer Pathologies by Multiplexed Spatial Proteomics;International Journal of Molecular Sciences;2024-06-19

2. Immune cell infiltrate in ductal carcinoma in situ and the risk of dying from breast cancer: case–control study;British Journal of Surgery;2024-01-31

3. The clinical significance of HER2 expression in DCIS;Medical Oncology;2022-11-09

4. Assessment of the usefulness of prognostic Van Nuys Prognostic Index in the treatment in ductal carcinoma in situ in 15-year observation;Scientific Reports;2021-11-22

5. Ultrasonography-Based Radiomics of Screening-Detected Ductal Carcinoma In Situ According to Visibility on Mammography;Ultrasound Quarterly;2020-11-13